A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study. (November 2020)

• Record Type: Journal Article
• Authors: Harrison, Stephen A; Ratziu, Vlad; Boursier, Jérôme; Francque, Sven; Bedossa, Pierre; Majd, Zouher; Cordonnier, Geneviève; Sudrik, Fouad Ben; Darteil, Raphael; Liebe, Roman; Magnanensi, Jérémy; Hajji, Yacine; Brozek, John; Roudot, Alice; Staels, Bart; Hum, Dean W; Megnien, Sophie Jeannin; Hosmane, Suneil; Dam, Noémie; Chaumat, Pierre; Hanf, Rémy; Anstee, Quentin M; Sanyal, Arun J
• Is Part Of: Lancet gastroenterology and hepatology. Volume 5:Number 11(2020)
• Page Start: 970
• Page End: 985
• Publication Date: 2020-11
• DOI: 10.1016/S2468-1253(20)30252-1
• Languages: English
• ISSNs: 2468-1253

Abstract

Summary: Background: Non-invasive tests that can identify patients with non-alcoholic steatohepatitis (NASH) at higher risk of disease progression are lacking. We report the development and validation of a blood-based diagnostic test to non-invasively rule in and rule out at-risk NASH (defined as non-alcoholic fatty liver disease [NAFLD] activity score [NAS] ≥4 and fibrosis stage ≥2). Methods: In this prospective derivation and global validation study, blood samples, clinical data, and liver biopsy results from three independent cohorts with suspected NAFLD were used to develop and validate a non-invasive blood-based diagnostic test, called NIS4. Derivation was done in the discovery cohort, which comprised 239 prospectively recruited patients with biopsy-confirmed NASH (NAFLD NAS ≥3; fibrosis stage 0–3) from the international GOLDEN-505 phase 2b clinical trial. A complete matrix based on 23 variables selected for univariate association with the presence of at-risk NASH and avoiding high multi-collinearity was used to derive the model in a bootstrap-based process that minimised the Akaike information criterion. The overall diagnostic performance of NIS4 was externally validated in two independent cohorts: RESOLVE-IT diag and Angers. The RESOLVE-IT diag cohort comprised the first 475 patients screened for potential inclusion into the RESOLVE-IT phase 3 clinical trial. Angers was a retrospective cohort of 227 prospectively recruited patients with suspected NAFLD and clinical risk factors for NASH or fibrosis stage 2 or more according to abnormal elastography results or abnormal liver biochemistry. Both external validation cohorts were independently analysed and were combined into a pooled validation cohort (n=702) to assess clinical performance of NIS4 and other non-invasive tests. Findings: The derived NIS4 algorithm comprised four independent NASH-associated biomarkers (miR-34a-5p, alpha-2 macroglobulin, YKL-40, and glycated haemoglobin; area under the receiver operating characteristics curve [AUROC] 0·80, 95% CI 0·73–0·85), and did not require adjustment for age, sex, body-mass index (BMI), or aminotransferase concentrations. Clinical cutoffs were established within the discovery cohort to optimise both rule out and rule in clinical performance while minimising indeterminate results. NIS4 was validated in the RESOLVE-IT diag cohort (AUROC 0·83, 95% CI 0·79–0·86) and the Angers cohort (0·76, 0·69–0·82). In the pooled validation cohort, patients with a NIS4 value less than 0·36 were classified as not having at-risk NASH (ruled out) with 81·5% (95% CI 76·9–85·3) sensitivity, 63·0% (57·8–68·0) specificity, and a negative predictive value of 77·9% (72·5–82·4), whereas those with a NIS4 value of more than 0·63 were classified as having at-risk NASH (ruled in) with 87·1% (83·1–90·3) specificity, 50·7% (45·3–56·1) sensitivity, and a positive predictive value of 79·2% (73·1–84·2). The diagnostic performance of NIS4 within the external validation cohorts was not influenced by age, sex, BMI, or aminotransferase concentrations. Interpretation: NIS4 is a novel blood-based diagnostic that provides an effective way to non-invasively rule in or rule out at-risk NASH in patients with metabolic risk factors and suspected disease. Use of NIS4 in clinical trials or in the clinic has the potential to greatly reduce unnecessary liver biopsies in patients with lower risk of disease progression. Funding: Genfit.